title: Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.
abstract: 3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two enantiomers, both of which are active in vivo. In this regard, among the substituted phenethylamines, R(-)-enantiomers tend to have hallucinogen-like effects, whereas S(+)-enantiomers tend to have stimulant-like effects. In the present study, mice were trained to discriminate S(+)- or R(-)-MDMA from vehicle. Drug substitution tests were then undertaken with the structurally similar phenethylamine dopamine/norepinephrine releaser S(+)-amphetamine, the structurally dissimilar tropane nonselective monoamine reuptake inhibitor cocaine, the structurally similar phenethylamine 5-hydroxytryptamine (5-HT)(2A) agonist 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), and the structurally dissimilar mixed action tryptamine 5-HT(2A) agonist/monoamine reuptake inhibitor N,N-dipropyltryptamine (DPT). S(+)-amphetamine fully substituted in the S(+)-MDMA-treated animals but did not substitute for the R(-)-MDMA cue. 2C-T-7 fully substituted in the R(-)-MDMA-trained animals but did not substitute for the S(+)-MDMA cue. Cocaine and DPT substituted for both training drugs, but whereas cocaine was more potent in S(+)-MDMA-trained mice, DPT was more potent in R(-)-MDMA-trained mice. These data suggest that qualitative differences in the discriminative stimulus effects of each stereoisomer of MDMA exist in mice and further our understanding of the complex nature of the interoceptive effects of MDMA.
authors.affiliation: Emory University, Neuroscience Graduate Program, Atlanta, Georgia, USA.
authors.forename: K S
authors.initials: KS
authors.lastname: Murnane
authors.forename: N
authors.initials: N
authors.lastname: Murai
authors.forename: L L
authors.initials: LL
authors.lastname: Howell
authors.forename: W E
authors.initials: WE
authors.lastname: Fantegrossi
mesh_terms: D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003042:Cocaine / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects; D004193:Discrimination Learning / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006213:Hallucinogens / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000737:chemistry / Q000494:pharmacology*; D010627:Phenethylamines / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013237:Stereoisomerism; D014363:Tryptamines / Q000494:pharmacology
chemical_list: D000662:Amphetamines; D000697:Central Nervous System Stimulants; D003042:Cocaine; D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D010627:Phenethylamines; D017367:Selective Serotonin Reuptake Inhibitors; D014363:Tryptamines; C487778:2,5-dimethoxy-4-n-propylthiophenethylamine; C029261:phenethylamine; C007528:dipropyltryptamine
references.citation: Behav Pharmacol. 1995 Apr;6(3):263-275
references.pmid: 11224335
references.citation: Psychopharmacology (Berl). 1997 Mar;130(1):2-13
references.pmid: 9089844
references.citation: Psychopharmacology (Berl). 2005 Sep;181(3):496-503
references.pmid: 15983786
references.citation: Eur J Pharmacol. 1988 Aug 2;152(3):227-34
references.pmid: 2906000
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:681-98
references.pmid: 17209801
references.citation: Neuropsychopharmacology. 1998 Oct;19(4):241-51
references.pmid: 9718588
references.citation: Pharmacol Biochem Behav. 2007 Nov;88(1):18-27
references.pmid: 17651790
references.citation: Biochem Pharmacol. 2008 Jan 1;75(1):17-33
references.pmid: 17977517
references.citation: Pharmacol Biochem Behav. 1988 Mar;29(3):443-9
references.pmid: 2896360
references.citation: J Psychopharmacol. 2006 Mar;20(2):194-210
references.pmid: 16510478
references.citation: Neuropharmacology. 1987 Nov;26(11):1657-61
references.pmid: 2448703
references.citation: Psychopharmacology (Berl). 2003 Mar;166(3):202-11
references.pmid: 12563544
references.citation: Psychopharmacology (Berl). 2005 Sep;181(3):529-36
references.pmid: 15983787
references.citation: Psychopharmacology (Berl). 1986;88(4):525-6
references.pmid: 2871581
references.citation: Drug Alcohol Depend. 1999 Aug 2;56(1):9-15
references.pmid: 10462087
references.citation: Neuropharmacology. 2001;40(1):65-74
references.pmid: 11077072
references.citation: Neuropsychopharmacology. 2000 May;22(5):513-21
references.pmid: 10731626
references.citation: Neuropsychopharmacology. 2000 Oct;23(4):396-404
references.pmid: 10989266
references.citation: Psychopharmacol Ser. 1988;4:161-75
references.pmid: 3293041
references.citation: J Pharmacol Exp Ther. 2002 Jun;301(3):1097-102
references.pmid: 12023542
references.citation: Neurosci Lett. 1994 Aug 15;177(1-2):111-5
references.pmid: 7824160
references.citation: Pharmacol Biochem Behav. 2005 Nov;82(3):531-8
references.pmid: 16337676
references.citation: Pharmacol Biochem Behav. 1999 Oct;64(2):283-93
references.pmid: 10515304
references.citation: Eur J Pharmacol. 2007 Mar 22;559(2-3):132-7
references.pmid: 17223101
references.citation: J Pharmacol Exp Ther. 2009 Jun;329(3):1006-15
references.pmid: 19276400
references.citation: Mol Pharmacol. 2003 Jun;63(6):1223-9
references.pmid: 12761331
references.citation: J Neurochem. 2007 Jul;102(1):121-32
references.pmid: 17564678
references.citation: Neuropharmacology. 1980 Aug;19(8):705-13
references.pmid: 7422085
references.citation: Pharmacol Rev. 2003 Sep;55(3):463-508
references.pmid: 12869661